Navigation Links
NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial
Date:12/16/2010

ROCKVILLE, Md., Dec. 16, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold.  In November, the company reported that it had received a question from the FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved.

Preclinical studies of Novavax's vaccine candidate to prevent RSV infection were conducted in cotton rats, a well-accepted animal model of RSV infection and disease. Results showed induction of neutralizing antibodies and protection from RSV challenge with no disease enhancement.  After the RSV challenge, no detection of disease was observed in any of the animals immunized with the vaccine candidate at any dose level tested.  Novavax's vaccine uses highly purified recombinant particles of RSV-F fusion protein normally found in the virus.  There is currently no approved vaccine to prevent RSV infection.

"We are excited to advance our vaccine candidate for RSV into clinical testing," said Dr. Rahul Singhvi, President and CEO of Novavax.  "This is a significant accomplishment and represents the second major internally discovered vaccine program based on our core platform technologies. RSV is the leading cause of viral death in infants and a common illness in elderly adults.  A safe and effective vaccine is especially needed in these populations since RSV infection does not provoke lasting immunity."  

About Respiratory Syncytial Virus

RSV is the most commonly identified cause of lower respiratory tract illnesses in infants and young children worldwide.  Repeated infections occur throughout life causing moderate to severe col
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NOVAVAX to Present at Lazard 7th Annual Healthcare Conference
2. NOVAVAX Reports Third Quarter 2010 Financial Results
3. Novavax to Report Third Quarter 2010 Financial Results on November 5, 2010
4. NOVAVAX to Present at BIO Investor Forum
5. NOVAVAX to Present at Stifel Nicolaus Conference
6. NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures
7. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
8. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010
9. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
10. NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results
11. NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ... decade has seen the atopic dermatitis market ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger ... and painless for patients to self-inject prescription drugs in ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and ... market is expected to grow to $220B by 2018, ... a new type of injector that does not exist ...
(Date:1/14/2014)... -- Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of ... Home Medical Equipment, Inc. ("Progressive") of Clarion, PA ... acquisition were not disclosed. Progressive is a ... range of sleep, mobility, and respiratory products to customers in ... Pittsburgh markets. Progressive was founded in 2005 by ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... N.J., Nov. 4, 2010 Savient Pharmaceuticals, Inc. (Nasdaq: ... to commence shipments of KRYSTEXXA™ to specialty distributors on ... enzyme indicated for the treatment of chronic gout in ... to be commercially available for prescription as of December ...
... Nov. 4, 2010 Stanley M. Chesley of the Cincinnati, ... L.P.A. earlier today filed a major class action lawsuit against ... DePuy and Johnson and Johnson recently recalled over ... an unacceptable failure rate causing patients to undergo hip replacement ...
Cached Medicine Technology:Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 2Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 3Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 4Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 5Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 6Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results 7
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... New Report Details the Structure and Funding Of U.S. ... With attention to global health rising on the ... Foundation today launched a set of new resources providing ... the global health arena with timely information, including daily ...
... Value Is Through A Sale to A Strategic Acquirer.RALEIGH, ... stockholder of BioScrip, Inc. (Nasdaq: BIOS ), ... the Board of Directors of BioScrip in which Anchor ... through simultaneous i) cost rationalizations and ii) exploration of ...
... N.C., April 27 Susan Brady of ... professionals in the nation to become certified by ... nonprofit organization that provides advocacy and education for ... demonstrated in-depth knowledge and expertise on best practices ...
... Monitoring Companies Demonstrates FORA Technology at Telemedicine Conference in ... Fora Care and Fora Care Suisse AG (Fora Care,s ... innovative telemedicine program at the American Telemedicine Association (ATA) ... Casino in Las Vegas, Nev. The veteran telemedicine ...
... Daily exposure to toxins in the products we ... insecticides, are creating a toxic load on our bodies ... In light of increased awareness of our environmental exposures, ... ) announced today the release of three new testing ...
... to 10-minute soaks, twice a week, prevent painful flare-ups, ... Diluted bleach baths offer a safe, simple and inexpensive ... researchers. , The skin disease, which affects 17 percent ... their ability to concentrate in school. , Eczema-related ...
Cached Medicine News:Health News:Kaiser Family Foundation Launches Daily Global Health Policy Report and Policy Tracking Tool As Part of New Web Gateway Focusing on U.S. Global Health Policy 2Health News:Kaiser Family Foundation Launches Daily Global Health Policy Report and Policy Tracking Tool As Part of New Web Gateway Focusing on U.S. Global Health Policy 3Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 2Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 3Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 4Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 5Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 6Health News:Anchor Capital Calls on BioScrip Board to Pursue Cost Reductions While Exploring Strategic Sale to Unlock Shareholder Value 7Health News:MedThink Communications Account Director Among First to Receive CMPP Certification in Medical Publications Planning and Development 2Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 2Health News:Fora Care and Fora Care Suisse AG Launch Diabetes Telehealth Solution at ATA 3Health News:Metametrix Announces New Toxic Effects Profiles to Help Combat Growing Concerns About Toxicity and Health 2Health News:Diluted Bleach Baths Ease Kids' Eczema 2
... Medtronic has been a key participant ... for more than a decade. Previous Medtronic ... for concentrated platelets, as well as to ... for producing platelet-rich plasma (PRP) for a ...
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
... Biliary Self-Expanding Stent System combines low-profile, high radial ... .018" guide wire compatible stent system provides 6F ... diameters (5.0 - 10.0 mm). Now, with longer ... in five stent lengths (28, 38, 56, 80 ...
... Supreme and Response catheters comprise ... catheters available for electrophysiology procedures. Their ... provide for superior torque response with ... multiple curves and French sizes, Supreme ...
Medicine Products: